Determination of a novel anticancer c-Met inhibitor LS-177 in rat plasma and tissues with a validated UPLC-MS/MS method: Application to pharmacokinetics and tissue distribution study

Biomedical Chromatography

Volumn 29, Issue 7, 2015, Pages 1103-1111

  Ju, Ping ^a   Liu, Zhenzhen ^a   Jiang, Yu ^a   Zhao, Simin ^a   Zhang, Lunhui ^a   Zhang, Yuanyuan ^a   Gu, Liqiang ^a   Tang, Xing ^a   Bi, Kaishun ^a   Chen, Xiaohui ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

LS 177; Pharmacokinetics; Tissue distribution; UPLC MS MS

Indexed keywords

BODY FLUIDS; DRUG DOSAGE; HISTOLOGY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; RATS; TISSUE; TISSUE ENGINEERING;

C-MET INHIBITORS; KINASE INHIBITORS; LS-177; MOLECULE KINASE; RAT PLASMA; RAT TISSUE; SIGNALLING PATHWAYS; SMALL MOLECULES; TISSUE DISTRIBUTIONS; UPLC-MS/MS;

PHARMACOKINETICS;

LS 177; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG TISSUE LEVEL; FEMALE; LIQUID LIQUID EXTRACTION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE HOMOGENATE; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG STABILITY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SPRAGUE DAWLEY RAT; STATISTICAL MODEL; TISSUE DISTRIBUTION;

RATTUS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG STABILITY; FEMALE; LINEAR MODELS; MALE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

EID: 84931956624     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.3397     Document Type: Article

References (24)

1. Besterman JM, Fournel M, Dupont I, Bonfils C, Dubay M, Ste-Croix H and Maroun CR. Potent preclinical anti-tumor activity of MGCD265, an oral Met/VEGFR kinase inhibitor in Phase II clinical development, in combination with taxanes or erlotinib. Journal of Clinical Oncology (Meeting Abstracts). 2010; 28(15 suppl.): e13595.
2. Cai ZW, Wei D, Schroeder GM, Cornelius LA, Kim K, Chen XT and Borzilleri RM. Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors. Bioorganic and Medicinal Chemistry Letters 2008; 18: 3224-3229.
3. Christensen JG, Burrows J and Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Letters 2005; 225(1): 1-26.
4. Eder JP, Shapiro GI, Appleman L, Zhu AX, Miles D, Keer H, Cancilla B, Chu F, Hitchcock-Bryan S, Sherman L, McCallum S, Heath EI, Boerner SA and LoRusso PM. A phase I dose-escalation study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and early antitumor activity of foretinib. Clinical Cancer Research 2010; 16(13): 3297.
5. Friedman JA, Donaldson R, Miknyoczki S, Cheng MG, Hudkins R, Dorsey B, Ator M, Angeles T, Ruggeri B and Bruckheimer E. Abstract C272: Antitumor activity of the dual AXL/c-Met inhibitor CEP-40783 in champions primary TumorGraft™ models of human non-small cell lung cancer (NSCLC). Molecular Cancer Therapeutics 2013; 12 (11 Supplement): C272-C272.
6. Gong P, Liu YJ, Zhao YF, Zhai X and Li S. (2-phenoxy) quinoline derivatives and their use. CN Patent ZL201310045375.5, 2013.
7. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Advanced Drug Delivery Reviews 2001; 47: 65-81.
8. Kurzrock R, Camacho L, Hong D, Ng C, Janisch L, Ratain MJ, Salgia R and Anderson MD. A phase I dose-escalation study of the safety and pharmacokinetics of a XL184, a VEGFR and Met kinase inhibitor, administered orally to subjects with advanced malignancies. European Journal of Cancer Supplements 2006; 4(12): 124-125.
9. Li S, Zhao YF, Wang KW, Gao YL, Han JM, Cui BB and Gong P. Discovery of novel 4-(2-fluorophenoxy) quinoline derivatives bearing 4-oxo-1, 4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors. Bioorganic& Medicinal Chemistry Letters 2013; 21: 2843-2855.
10. LoRusso P, Appleman L, Heath E, Malburg L, Zhu AX, Carey M, Shapiro GI and Eder JP. A phase I study of a novel spectrum-selective kinase inhibitor(SSKI), XL880, administered orally in patients with advanced solid malignancies(ASM). Journal of Clinical Oncology 2006; 24(18): 131S-131S.
11. Mannion M, Raeppel S, Claridge S, Zhou N, Saavedra O, Isakovic L and Vaisburg A. N-(4-(6, 7-disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors. Bioorganic and Medicinal Chemistry Letters 2009; 19: 6552-6556.
12. Naing A, Kurzrock R, Adams LM, Kleha JF, Laubscher KH, Bonate PL, Weller S, Fitzgerald C, Xu YM and LoRusso PM. A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors. Investigational New Drugs 2012; 30(1): 327-334.
13. Porter J. Small molecule c-Met kinase inhibitors: a review of recent patents. Expert Opinion on Therapeutic Patents 2010; 20: 159-177.
14. Qian F, Engst S, Yamaguchi K, Yu PW, Won K, Mock L, Lou T, Tan J, Li C, Tam D, Lougheed JL, Yakes FM, Bentzien F, Xu W, Zaks T, Wooster R, Greshock J and Joly AH. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Research 2009; 69(20): 8009-8016.
15. Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, Dinali M, Yala S, Kanteti R, Cohen EEW, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE and Salgia R. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Research 2013; 69: 3021-3031.
16. Shapiro GI, McCallum S, Adams LM, Sherman L, Weller S, Swann S, Keer H, Miles D, Müller T and Lorusso P. A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors. Investigational New Drugs 2013; 31(3):742-750.
17. Stellrecht CM and Gandhi V. MET receptor tyrosine kinase as a therapeutic anticancer target. Cancer Letters 2009; 280(1): 1-14.
18. Suárez RM, Chevot F, Cavagnino A, Saettel N, Radvanyi F, Piguel S, Bernard-Pierrot I, Stoven V and Legraverend M. Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation. European Journal of Medicinal Chemistry 2013; 61: 2-25.
19. Sun Q, Ng C, Guy GR and Sivaraman J. An adjacent arginine, and the phosphorylated tyrosine in the c-Met receptor target sequence, dictates the orientation of c-Cbl binding. FEBS Letters 2011; 585: 281-285.
20. Tang QD, Zhao YF, Du XM, Chong LE, Gong P and Guo C. Design, synthesis, and structure-activity relationships of novel 6, 7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents. European Journal of Medicinal Chemistry 2013; 69: 77-89.
21. Underiner TL, Herbertz T and Miknyoczki SJ. Discovery of small molecule c-Met inhibitors: evolution and profiles of clinical candidates. Anti-Cancer Agents in Medicinal Chemistry 2010; 10(1): 7-27.
22. US Food and Drug Administration. FDA Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Rockville, MD, 2001.
23. Xie B, Xing R, Chen P, Gou YB, Li S, Xiao J and Dong JH. Down-regulation of c-Met expression inhibits human HCC cells growth and invasion by RNA interference. Journal of Surgical Research 2010; 162(2): 231-238.
24. Zillhardt M, Park SM, Romero IL, Sawada K, Montag A, Krausz T, Yamada S, Peter ME and Lengyel E. Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. Clinical Cancer Research 2011; 17(12): 4042-4051.